HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Intellia Therapeutics, Inc.

Contributing Author

Recent Articles by Intellia Therapeutics, Inc.

Jan-07
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference NTLA GlobeNewswire
Jan-02
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Dec-05
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Nov-10
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy NTLA GlobeNewswire
Nov-08
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema NTLA GlobeNewswire
Nov-06
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates NTLA GlobeNewswire
Oct-27
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) NTLA GlobeNewswire
Oct-03
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Sep-25
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy NTLA GlobeNewswire
Sep-22
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy NTLA GlobeNewswire
Sep-18
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema NTLA GlobeNewswire
Aug-07
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
Aug-01
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jul-31
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates NTLA GlobeNewswire
Jul-07
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jun-15
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress NTLA GlobeNewswire
Jun-05
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
May-18
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting NTLA GlobeNewswire
May-08
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
May-06
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.